Severe, symptomatic, dose-limiting hypophosphatemia induced by hepatic arterial infusion of recombinant tumor necrosis factor in patients with liver metastases
- 15 May 1991
- Vol. 67 (10) , 2459-2461
- https://doi.org/10.1002/1097-0142(19910515)67:10<2459::aid-cncr2820671011>3.0.co;2-l
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Metabolic effects of tumour necrosis factor alpha in NMRI miceBritish Journal of Cancer, 1990
- Phase I trial of intramuscularly administered tumor necrosis factor in patients with advanced cancer.Journal of Clinical Oncology, 1989
- A phase I clinical trial of recombinant human tumor necrosis factorCancer, 1988
- A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients.Journal of Clinical Oncology, 1988
- Effect of recombinant cytokines on glycolysis and fructose 2,6-bisphosphate in rheumatoid synovial cells in vitroBiochemical Journal, 1988
- Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism.Journal of Clinical Oncology, 1988
- Recombinant Human Tumor Necrosis Factor-α: Effects on Proliferation of Normal and Transformed Cells in VitroScience, 1985
- Effect of Hypophosphatemia on Myocardial Performance in ManNew England Journal of Medicine, 1977